Study Objectives: To examine and compare the arousability threshold and fall risk upon awakening of doxepin (6 mg) versus zolpidem (10 mg). Methods: A total of 52 healthy adult males were included in a double-blind, placebo-controlled, four-way crossover study. The experimental procedure included four nights with polysomnography in the lab (zolpidem, doxepin, and their respective placebo conditions). Arousability was measured using an auditory awakening threshold delivered at the peak-plasma concentration for the active hypnotics and at matched times for the respective placebo conditions. Fall risk during the night was measured following awakening using the Berg Balance Scale and the Tandem Walk Task. Results: Both arousability and fall risk were lower in the doxepin condition compared to the zolpidem condition. Furthermore, arousability and fall risk for doxepin did not differ significantly from the placebo conditions. A significantly greater proportion of participants in the zolpidem condition (63.5%) did not wake until receiving the loudest tone (110 dB) as compared to the doxepin (17.6%) and placebo conditions (17.3%, 5.8%). Conclusions: Results suggest that zolpidem has greater risks for balance and awakening threshold compared with low-dose doxepin. Future prospective studies should extend results to clinical samples with population-level risk of injury and arousability.
INTRODUCTION

Prescription rates for hypnotics have increased in the United
States in the past two decades. [1] [2] [3] The primary goal of hypnotic treatment of insomnia is to promote sleep onset and maintenance through the sleep period. However, a potential side effect of hypnotics is that they can blunt arousal, or the ability to awaken, in response to internal and external stimuli such as a crying baby or a fire alarm. In such situations, patients taking hypnotics must not only be readily awakened but must also retain psychomotor functioning (such as gait and balance) so they may get out of bed and navigate their environment without falling. Arousability and fall risk during the sleep period are thus critical to assessing the risk-benefit ratio of a hypnotic, especially when tailoring treatment to specific populations, such as the elderly and patients with nocturia.
A growing literature suggests that hypnotics-in particular benzodiazepine receptor agonists (BzRAs)-may reduce ability to arouse during nocturnal sleep [4] [5] [6] and increase fall risk following awakenings. [7] [8] [9] Zolpidem is a BzRA and is the most commonly prescribed hypnotic in the United States. 2, 10, 11 Like all BzRAs, zolpidem promotes sleep by facilitating gamma-aminobutyric acid-ergic (GABAergic) inhibitory activity. However, this inhibitory mechanism is nonspecific because it acts on the GABA-A receptor, which accounts for nearly 30% of all synapses in the central nervous system (CNS) and is involved in almost every behavioral system including balance. 12 Some but not all epidemiological and experimental studies point to an association between zolpidem use and increased fall risk. 8, 13, 14 A pressing question, therefore, is whether newer Food and Drug Administration (FDA)-approved medications with other mechanisms of action, such as doxepin, are safer in terms of arousability and fall risk. As opposed to the global CNS suppression of zolpidem, low-dose doxepin (≤6 mg) is more specified in its neurochemical target by impacting the wake-promoting system as a highly selective H 1 antagonist. Clinical research indicates that low-dose doxepin significantly improves sleep maintenance difficulties and extends total sleep time (TST) in individuals with insomnia. 15, 16 This different and more specific mechanism has been reported to have a more favorable risk-benefit ratio compared to BzRAs. 15, 16 However, there have been no head-to-head trials comparing the effects of doxepin relative to zolpidem on arousability and fall risk during the night.
The objective of this randomized, double-blind, placebo-controlled, four-way crossover trial was to determine the relative effects of zolpidem (10 mg) and doxepin (6 mg) on arousability and fall risk upon awakening. Specifically, forced awakenings, per a standardized auditory awakening threshold (AAT) protocol, were conducted at peak-plasma concentration (T-max) modeled on pharmacokinetic research for the active hypnotics and at matched times for the respective placebo conditions. T-max constitutes the period of greatest risk. Participants were restricted to healthy males to minimize confounds due to gender or underlying sleep disorder/medical condition, and to reduce heterogeneity in dosage given the FDA recommendation of 5 mg of zolpidem for women.
Statement of Significance
There is growing concern regarding the side effects of sedative hypnotics especially in regard to arousability and fall risk, which are critical for safety when responding to nighttime stimuli, such as a fire alarm or a crying baby. This study presents preliminary evidence suggesting that low-dose doxepin may have less impairment in arousability and risk for falls during the night compared to zolpidem. Future studies may explore the effectiveness of low-dose doxepin as an alternative for clinical populations that have concerns for nighttime arousability and risk for falls.
METHODS
This study was a double-blind, placebo-controlled, fourway crossover trial conducted from February 2015 through December 2015 at the Henry Ford Health Systems (HFHS). The study was approved by the HFHS Institutional Review Board, and written informed consent was provided by all participants before study procedures.
Participants
Healthy males between 21 and 50 years of age (inclusive) were screened for eligibility via a phone interview. Inclusion criteria were: stable maintenance of a habitual sleep schedule, including a nightly TST between 7 and 9 hours, and a habitual bedtime between 10:00 pm and 12:00 am. Participants meeting these initial screening criteria were invited for a physical examination (vitals, height, weight), blood draw (serum chemistry, hematology), urine drug screen (amphetamines, barbiturates, benzodiazepines, cocaine, opiates, or cannabinoids), and evaluation by a sleep-boarded physician. Exclusion criteria were: body mass index >35 kg/m 2 ; positive urine drug screen; abnormal hematology/serum chemistry values; current use of any medications known to affect sleep/wake; physician determined diagnosis of a sleep disorder (eg, insomnia, restless legs syndrome); current use of cimetidine or a monoamine oxidase inhibitor; known sensitivity; or history of adverse reactions to zolpidem or doxepin.
After initial screening screening interview and labs, participants received a standardized sleep diary 17 to complete over the next 7 days. Exclusion criteria were: TST < 7 or > 9 hours on > two nights; bedtime before 10:00 pm or after 12:00 am on > two nights; daytime napping on > 2 days; or incomplete data (< 5 complete diary entries). Finally, participants that met above criteria returned to the laboratory for a single night of overnight polysomnography (PSG) using standardized procedures to establish baseline sleep and rule out primary sleep disorders. Exclusion criteria were: Apnea Hypopnea Index >10 or Periodic Limb Movement Arousal Index > 10.
Procedures
Following the baseline PSG, eligible participants underwent four double-blind treatment periods. Each period comprised of drug administration at bedtime, provided to the research staff in a blinded fashion. All experimental medications were visually identical. Testing to assess for arousability and subsequent fall risk (as impacted by gait and balance) was conducted in all treatment periods by trained research technicians. Drugs were administered as a single dose and under fasted conditions (at least 4 hours). Lights out occurred immediately after drug administration and was followed by continuous PSG recording for 9 hours (eg, 11:00 pm to 08:00 am). Standardized AAT testing was conducted at T-max for the study drugs: 1.5 hours following administration for zolpidem and 4 hours following administration for doxepin. Testing occurred at matched times for the two placebo conditions: 1.5 hours after drug administration to match the zolpidem condition and after 4 hours to match the doxepin condition. The sequence of treatment periods was determined using a balanced four-way Latin-square crossover design and was only available to one research team member (PC) who did not have any participant contact during the experiment. Treatment periods within a sequence were separated by a 6-11 day washout. Significant confounding health events that may have occurred during the washout period were assessed at the beginning of each experimental visit, and no participants reported significant health events.
OUTCOME MEASURES
Auditory Awakening Threshold
Testing of the AAT occurred at the respective T-Max times (1.5 or 4 hours after drug administration) and following five consecutive minutes of nonrapid eye movement stage 2 sleep. An acoustic stimulus (1000 Hz tone) was presented through audiometric earphones (E-A-RTone 3A Insert Earphones). Tones began at 30 dB and increased by 5 dB until the participant woke up or the maximum dB-level (110 dB) was reached. Participants were considered awake when they said, "I am awake" via an intercom device. Each tone was presented for 3 seconds and was followed by a 15-second interval before the next incremental tone. Notably, the final 110 dB tone was played repeatedly (3-second tone at 15-second intervals) until the participant woke up or for a maximum of 2 minutes. Participants who did not wake despite receiving this final tone for 2 minutes were woken up by the experimenter. The awakening threshold was operationalized as the decibel level of the tone that resulted in an awakening. In case the participant had to be woken up by the experimenter, the maximal dB level (110 dB) was considered the AAT.
Berg Balance Scale
Fall risk as impacted by gait was measured using the Berg Balance Scale (BBS). The BBS 18 is a widely used clinical test of static and dynamic balance abilities. Comprising of 14 simple balance-related tasks, ranging from standing up from a sitting position to standing on one foot, the BBS takes 15-20 minutes to complete. Each component task is scored on a Likert scale: 0 (unable to perform) to 4 (performed independently). The sum of component scores yields the final BBS score (≤20: high fall risk; 21-40: medium fall risk; 41-56: low fall risk).
Tandem Walk Task
Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. A TWT involves five consecutive tandem walks from one end of a narrow beam (9-feet long; 4-inches wide) to another. 19 This test is not only an indicator of overall balance but is also a reliable predictor of falls. 20, 21 Primary end points were the number of step-offs from the beam and mean completion duration over the five trials.
Sleep PSG data was scored by a blinded certified sleep technician according to standardized American Academy of Sleep Medicine guidelines. Sleep measures included sleep onset latency (SOL), latency to persistent sleep (LPS), wake-time after sleep onset (WASO), and percentages of sleep stages. Adverse events (AEs) were assessed throughout the study.
Statistical Analysis
Statistical analyses were conducted using IBM SPSS Statistics-Version 23 (Armonk, New York). 22 Continuous variables such as AAT, BBS, number of step-offs, and mean duration for the TWT were characterized with means and standard deviations. Nominal data including participants who received the 110 dB tone and those that did not wake at the tone were characterized by percentages who met the criteria. A repeated-measures analysis of variance (ANOVA) was used to examine the continuous variables, followed by an examination of the six pairwise comparisons using paired t-tests. These analyses had a single within-factor condition (zolpidem, placebo-1.5H, doxepin, placebo-4H). Hochberg's method was used to determine significance and to correct for multiple testing. The nominal data formed a matched set of quadruples. Analysis of these data followed a method proposed by Cochran for the comparison of percentages in matched samples. 23 The pairwise comparisons were examined using McNamara's method. A Hochberg's adjustment was used to determine significance.
RESULTS
Participant Characteristics
After the in-lab screening and baseline PSG, 10 individuals were excluded for failure to meet entry criteria. Fifty-two participants (mean [standard deviation {SD}] age, 32.8 [7.6] years) were randomized, though one participant withdrew after completing three of the four conditions (doxepin condition not completed). The majority of participants identified as "white" (57.7%), though some racial/ethnic diversity was observed ("Asian," 9.6%; "African American," 5.8%). The majority of participants (82.3%) were employed full time, and 43.1% were married.
Polysomnography
PSG recordings were performed at lights out immediately after study drug administration. The overall recording duration was 8 hours for the baseline night and 9 hours for the experimental nights in order to account for testing in the middle of the night. Descriptive statistics for all PSG-defined sleep variables by condition appear in Table 1 . As expected from a sample of healthy adults, all baseline PSG sleep parameters were in the normative range. Pairwise planned comparisons were conducted for number of awakenings, WASO, SOL, LPS, and sleep efficiency (SE). The number of awakenings in each of the treatment medications was significantly different than their respective placebos (see Table 1 ; p < .05 for all). WASO decreased for zolpidem and doxepin compared to respective placebos (see Table 1 ; p < .05 for all). SE increased for both zolpidem and doxepin relative to placebo (see Table 1 ; p < .05 for all). No significant differences were detected for SOL and LPS.
PRIMARY OUTCOMES
Auditory Awakening Threshold
Descriptive statistics for the AAT at T-max for the active hypnotics and matching placebo conditions are presented in Figure 1 . A repeated-measures ANOVA examining AAT threshold across conditions was statistically significant, F = 24.5; p < .01. AAT in the doxepin condition (mean = 85.2, SD = 17.1) Indicates planned pairwise comparisons were performed. Significant differences between drug and the respective placebo indicated in bold. No significant differences were detected between zolpidem and doxepin for any comparisons. REM = rapid eye movement.
was significantly lower compared to zolpidem (mean = 103.2, SD = 11.8), t(102) = 6.3, p < .0001, and also differed significantly from its respective placebo, t(101) = 2.0, p < .05 (see Figure 1 ). Pairwise comparisons also showed that AAT in the zolpidem condition was significantly higher compared to placebo conditions (see Figure 1) . A Cochran-Mantel-Haenszel test indicated that the proportion of participants who did not wake until receiving the loudest tone (110 dB) was different between the conditions, χ 2 (3) = 53.10, p < .001. The McNemar's test indicated that the proportion was significantly lower in the doxepin condition (17.3%) compared to the zolpidem condition (63.5%; see Figure 1 ), χ 2 = 16.53, p < .001). Pairwise comparisons also showed that the proportion of individuals who did not wake until the loudest tone in the zolpidem condition was also significantly higher than the placebo conditions (zolpidem compared to placebo-1.5H: χ 2 = 20.35, p < .001; zolpidem compared to placebo-4H: χ 2 = 28.03, p < .001) and that the proportions did not differ between the doxepin and placebo conditions. The percentage of participants who did not wake despite receiving the maximum 110 dB tone for 2 minutes was also significantly different between the groups, χ 2 (3) = 35.00, p < .001 (see Figure 1) . Due to the smaller number of individuals in this category, the McNemar's test utilized the exact binomial test to assess for statistical significance. Pairwise comparisons showed that the zolpidem condition results in the highest proportion of individuals who did not wake to the loudest tone (38.5%) and differed significantly from the doxepin (7.8%; p < .01), placebo-1.5H (5.8%; p < .001), and placebo-4H conditions (3.8%; p < .001). The doxepin condition did not show any significant differences from the two placebo conditions.
Fall Risk
A repeated-measures ANOVA on BBS scores across conditions was statistically significant, F = 26.7, p < .01. Mean balance scores in the doxepin condition (mean = 54.5, SE = 0.26) was significantly higher (indicating better balance) than zolpidem (mean = 51.4, SE = 0.61), t(50) = 4.7, p < .0001 and did not differ from the placebo conditions (see Figure 2) . Balance scores for the zolpidem condition were also lower than the placebo conditions.
A repeated-measures ANOVA on number of step-offs was also statistically significant, F = 36.7, p < .01. Pairwise comparisons similarly indicated significantly fewer step-offs in the doxepin condition (mean = 1.5, SE = 0.33) compared to the zolpidem condition (mean = 8.1, SE = 1.11), t(50) = 6.14, p < .0001.
Step-offs in the doxepin condition did not differ from the placebo conditions, whereas step-offs in the zolpidem condition was higher than the placebo conditions (see Figure 2) .
With respect to mean duration for completion of the TWT, a repeated-measures ANOVA was statistically significant, F = 18.8, p < .01. Pairwise comparisons showed that mean duration of task completion in the doxepin condition (mean = 5.0 seconds, SE = 0.22) was significantly lower than the zolpidem condition (mean = 6.7 seconds, SE = 0.36), t(50) = 5.33, p < .0001 and did not differ from the placebo conditions (see Figure  2) . Duration of task completion for the zolpidem condition was also significantly higher than the placebo conditions.
One or more AEs were reported by eight participants (15%) who were exposed to zolpidem, nine participants (18%) during exposure to doxepin, and five (10%) and six participants (12%) for each respective placebo condition (see Table 2 for counting specific types of AEs). AEs were defined by any negative event experienced by a participant during the study (assessed in the morning prior to participants leaving the lab) and included the washout period following each treatment.
DISCUSSION
This study compared the effects of zolpidem 10 mg and doxepin 6 mg at T-max on AAT and fall risk (as impacted by gait and balance) and is the first study to compare these outcomes between zolpidem and doxepin. Findings were remarkably consistent across all assessed indices of arousability and fall risk and indicated that zolpidem was associated with significantly greater risks than both placebo and low-dose doxepin. The AAT was significantly higher in the zolpidem condition than all other conditions, with over 60% of the sample unresponsive to auditory stimuli below 110 dB, which is akin to the noise level at a live rock concert. Notably, smoke detectors emit an average of 85 dB, which is comparable to the AAT detected in the doxepin and placebo conditions. The AAT in the doxepin condition was higher than its respective placebo condition, with a difference of approximately 7 dB which corresponds to an increase of between 50% and 100% in perceived volume. 24, 25 This suggests that low-dose doxepin could have a better risk-benefit ratio for sleep maintenance in regard to ambient noise, as it appears to raise the AAT above placebo but not above standard emergency signals such as smoke detectors.
Results on tasks assessing fall risk also indicated better performance on doxepin compared to zolpidem. While mean BBS scores across all conditions were in the low risk range, scores in the doxepin condition were higher than the zolpidem condition. However, a count of scores at or below 45 as a threshold of fall risk 26 revealed 7 in the zolpidem condition, 0 in both the doxepin and placebo (4H) conditions, and 1 in the placebo (1.5H) condition. Additionally, comparisons with data collected in community-dwelling elderly adults (age brackets 60-69, 70-79, and 80-89) indicated that the mean score in the zolpidem condition fell within the 95% confidence interval of scores obtained in 80-to 89-year-old adult males. 27 In contrast, mean scores in the doxepin and control conditions were comparable to performance of adult males one to two decades younger. Furthermore, the zolpidem condition also led to longer task completion time and more step-offs on the TWT. These data suggest that individuals may be at lower risk for falls due to gait and balance issues on doxepin compared to zolpidem. Moreover, participants in the doxepin condition did not exhibit any evidence of impairment on these tasks relative to placebo. In the current climate of heightened concerns about the overuse of BzRAs, especially among the elderly, these findings may carry significant health implications. 28 Falls represent a serious health risk in elderly patients, and numerous epidemiological studies have implicated zolpidem use as a contributing factor to falls and hip fractures in the elderly. While the current study is limited by its focus on healthy adult males who are at low risk for falls, we would expect that risk for falls would be magnified in a more vulnerable population like the elderly; however, further research in clinical populations must be conducted to examine this hypothesis. Finally, this study was restricted to males in order to attain more control as an efficacy study, particularly because of sex differences in dosage for zolpidem. Future research may use hypnotics without gender difference as comparators, though the generalizability may be more limited, as zolpidem is the most widely prescribed hypnotic; however, this may be balanced by the opportunity for inclusion of females, which is especially relevant to insomnia given the higher prevalence rate in females than males. Despite these limitations, the current findings add to the much needed controlled laboratory data to this literature and provide support for continued clinical research.
As expected, both zolpidem and doxepin were well tolerated and improved several indices of sleep relative to placebo, including SE and WASO. SOL in the two active drug conditions was not significantly different from placebo; however, this may be a reflection of range restriction on this particular sleep parameter given that participants were healthy adults. Further, only a single dose of each drug was tested, and therefore, it is hard to discern between drug-specific versus dose-related differences. However, the strategy used employed the highest dose of each drug approved for use. Future studies may benefit from analyzing multiple doses of these agents to derive dose-response curves and establish equipotency.
With a growing concern regarding risks associated with BzRAs, this study provides preliminary evidence that doxepin may be considered as an alternative prescription sleep aid to BzRAs; however, this should be confirmed in further studies, particularly in individuals at higher risk for falls such as the elderly, before it should be prescribed as such. As opposed to the nonspecific GABAergic inhibitory activity of BzRAs that acts to suppress CNS activity globally, doxepin has the advantage of increased specificity in targeting the wake-promoting system via high affinity binding to histamine H 1 receptors. As such, other domains of functioning such as balance may be more Other 2% (1) 8% (7) 4% (2) 2% (1) Total adverse events (AEs) = 46 (13% of participants reported > 1 AE, n = 7).
